![Tanja Obradovic: Private Biotech investment is on the steady rise reaching $3.1 billion in April](https://oncodaily.com/pub/uploads/2024/05/Screenshot-2024-05-13-at-3.38.06 PM-1.png)
Tanja Obradovic: Private Biotech investment is on the steady rise reaching $3.1 billion in April
Tanja Obradovic, Vice President of Oncology Scientific Affairs at
“Private Biotech investment is on the steady rise reaching new highs in April with $3.1 billion raised that is surpassing previous three months activity according to Labiotech.eu report.
In terms of geography, Europe and Asia-Pacific are trailing US. Among specific therapeutic areas Biotech companies developing Oncology assets are attracting largest investment that went solely to US and Asia-Pacific regions. This brings a question if European Biotech companies developing Oncology drugs face some unique challenges despite a very active recent trend of M&A. During 2023 there was high activity involving European based Biotechs with oncology pipeline. Interest in ADCs drove a licensing deal between Synaffix and MacroGenics, followed by the acquisition of Synaffix by Lonza. In addition, radiopharmaceutical Biotech ITM Isotope Technologies Munich raised one of the largest private investment rounds in European Biotech in 2023.
In 2024 MorphoSys was acquired by Novartis, RedX Pharma was acquired by Jazz Pharmaceuticals, and Autolus Therapeutics was acquired by Bio NTech SE in February. Interesting to follow trends for Europe and see if there is influence of fragmented nature of the EU healthcare market making drug adoption prediction complex, possibly more risk-averse approach of EU-based buyers, as well as evolution of global reimbursement market on financial dynamics of the EU Biotech activity.”
Source: Tanja Obradovic/LinkedIn
OncoDaily
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023